FDA Seeks to Restrict Rucaparib to Second-line Maintenance Therapy in Recurrent Ovarian Cancer

November 18, 2022 11:51 am

by Jason Harris

The FDA has asked Clovis Oncology to limit use of rucaparib (Rubraca) to second-line maintenance therapy for patients with recurrent ovarian cancer harboring BRCA mutations.1

fdaThe company is considering the FDA’s request. If the 2 sides

Read more

FDA Requests Restriction of Second-line Maintenance Niraparib Indication in Ovarian Cancer

November 14, 2022 11:41 am

by Kristi Rosa

At the request of the FDA, GlaxoSmithKline (GSK) plc will restrict the second-line maintenance indication for niraparib (Zejula) to only the population of patients with recurrent ovarian cancer whose tumors harbor deleterious or suspected deleterious germline BRCA

Read more

Penn Study Illuminates Why Cancers Caused by BRCA Mutations Recur

November 10, 2022 11:36 am

Findings uncover possible drivers of recurrent breast and ovarian cancers among women carrying high-risk genetic mutations, pointing to methods to more effectively treat disease

PHILADELPHIA — Researchers at the University of Pennsylvania’s Basser Center for BRCA at the Abramson Cancer … Read more

Pembrolizumab Plus Bevacizumab and Cyclophosphamide Shows Promising Efficacy, Tolerability in Recurrent Ovarian Cancer

September 26, 2022 9:49 am

by Megan Hollasch

Real-world data from a retrospective study showed that pembrolizumab combined with the anti-VEGF agent bevacizumab plus oral metronomic cyclophosphamide displayed minimal toxicity in a significant number of patients with recurrent epithelial ovarian, fallopian tube, or primary peritoneal Read more

FDA Grants First Tumor-Agnostic Approval for RET Fusion-Positive Cancers

September 22, 2022 9:49 am

by Mike Bassett

— Selpercatinib approved for advanced or metastatic solid tumors that progress on systemic therapy

The FDA granted accelerated approval to selpercatinib (Retevmo) for adults with locally advanced or metastatic solid tumors associated with RET gene fusions, the

Read more

Phase 1 Success of Targeting MUC16 in Patients With Recurrent Ovarian Cancer

September 14, 2022 1:11 pm

by Jordyn Sava

In an interview with Targeted Oncology during the EMSO Annual Congress, David O’Malley, MD, discussed the phase 1 study of ubamatamab in ovarian cancer.

Ubamatamab, a novel MUC16 antibody, demonstrated evidence of durable responses in patients with … Read more

TCR T-Cell Therapy Shows Efficacy Across MAGE-A4+ Solid Tumors

September 10, 2022 10:50 am

by Victoria Johnson

ADP-A2M4CD8 will be evaluated in the phase 2 SURPASS-3 trial initiating in late 2022 or early 2023.

ADP-A2M4CD8, a CD8+ T-cell receptor (TCR) engineered T-cell therapy has yielded responses across a variety of MAGE-A4+ solid tumors, including

Read more

Immune receptors recognizing mutations in p53 could guide immunotherapies for solid tumors

September 6, 2022 1:48 pm

CCR scientists have identified dozens of naturally occurring receptors that direct immune cells to tumors with mutations in p53, the most commonly mutated gene in human cancers. The research team, led by Steven Rosenberg, M.D., Ph.D., Chief of the … Read more

DS-6000a Displays Early Clinical Activity in Ovarian Cancer and RCC

August 24, 2022 2:20 pm

In an interview with Targeted Oncology, Erika P. Hamilton, MD, discussed the early clinical activity seen with DS-6000a in patients with advanced ovarian cancer or renal cell carcinoma with disease progression following standard of care treatment.

Interim data from a … Read more

A Behind-the-Scenes Look at My Cancer Clinical Trial Experience

June 1, 2022 11:07 am

by Kelly Irvin

It’s good to have all the facts when you decide whether to participate in a cancer drug clinical trial—even the ones that make you swallow hard and tear up.

To find clinical trials, please check out the Read more

Break Through Cancer Announces $50 Million in Grants to Researchers From Five Top Cancer Research Centers

April 19, 2022 9:13 am

by the ASCO Post Staff

Today, 1 year after its founding, Break Through Cancer announced $50 million in grants to support several cutting-edge research projects using a novel “TeamLab” structure—designed to maximize interdisciplinary collaboration among researchers at Dana-Farber Cancer Institute, … Read more

Elimusertib Shows Promise for Solid Tumors With ATM Loss and DDR Gene Defects

April 10, 2022 2:29 pm

by Ariana Pelosci

Data regarding different dosing strategies of elimusertib for advanced solid tumors with ATM alterations and other DNA damage repair gene defects display early efficacy of the therapy.

Patients with advanced solid tumors who have ATM gene alterations

Read more

Nemvaleukin Alfa Plus Pembrolizumab Demonstrates Promising Responses, Disease Control in Platinum-Resistant Ovarian Cancer

March 20, 2022 9:55 am

by Hayley Virgil

Patients with pretreated ovarian cancer who are resistant to platinum-based chemotherapy may experience promising responses and disease control following treatment with nemvaleukin alfa and pembrolizumab.

Treatment with nemvaleukin alfa (ALKS 4230) plus pembrolizumab (Keytruda) yielded tumor responses

Read more

New Drug Combination Shown Effective for Patients With Advanced Ovarian Cancer

February 14, 2022 10:17 am

by Anne Doerr

A new study led by researchers at Yale Cancer Center and the University of Maryland Greenebaum Comprehensive Cancer Center shows ixabepilone plus bevacizumab (IXA+BEV) is a well-tolerated, effective combination for treatment of platinum/taxane-resistant ovarian cancer compared to … Read more

Virtual Surveillance Visits with Symptom, Serum CA-125 Review May Offer Alternative for Ovarian Cancer Recurrence Detection.

February 1, 2022 12:37 pm

by Monica Janke, MD

In patients with ovarian cancer and pretreatment elevated CA-125 who achieved remission after frontline therapy, most recurrences are detected by rising CA-125 levels or symptoms.

In patients with ovarian cancer and pretreatment elevated CA-125 who achieved

Read more

STRO-002 Produces Deep Responses in Heavily Pretreated Advanced Ovarian Cancer

January 7, 2022 11:18 am

by Kristi Rosa

The FolRα-targeted antibody-drug conjugate STRO-002 was found to elicit encouraging responses in heavily pretreated patients with advanced ovarian cancer.

The FolRα-targeted antibody-drug conjugate (ADC) STRO-002 was found to elicit encouraging responses in heavily pretreated patients with advanced

Read more

AGO Score Identifies Ovarian Cancer Patients Likely to Benefit from Cytoreductive Surgery

December 6, 2021 2:29 pm

by Sucharita Mistry, PhD

Cytoreductive surgery followed by chemotherapy can prolong overall survival (OS), compared with chemotherapy alone, in certain patients with relapsed ovarian cancer, according to results from the DESKTOP III trial published in the New England Journal of Read more

Mirvetuximab Elicits Responses in More Than 31% of Patients With FRalpha-High Platinum-Resistant Ovarian Cancer

November 30, 2021 12:10 pm

by Nichole Tucker

Top-line results from the phase 3 SORAYA study show promise for mirvetuximab in patients with FRα-high platinum-resistant ovarian cancer.

Single-agent mirvetuximab soravtansine (mirvetuximab; IMGN853) has demonstrated clinically meaningful benefit in patients with late receptor alpha (FRα)-high platinum-resistant

Read more

Biomarker May Help to Predict Response to Gemcitabine for Patients With High-Grade Serous Ovarian Cancer

September 30, 2021 2:05 am

By The ASCO Post Staff

For more than 2 decades, the chemotherapy agent gemcitabine has been a mainstay treatment for several types of cancer. Now, scientists have uncovered genetic evidence of which patients with high-grade serous ovarian cancer are likely … Read more

Intermittent Relacorilant Combined with Nab-paclitaxel Improves PFS in Recurrent Platinum-Resistant Ovarian Cancer

September 17, 2021 4:47 pm

In the first randomised, controlled study to explore the efficacy and safety of relacorilant, a selective glucocorticoid receptor modulator, in combination with nab-paclitaxel compared to nab-paclitaxel alone, combined treatment improved progression-free survival (PFS) and showed a favourable safety profile among … Read more